Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00421031 | Study Evaluating the Safety & Efficacy of DVS-223 SR for Relief of Vasomotor Symptoms Associated With Menopause | PHASE3 | COMPLETED | 540 | — | — | Dec 1, 2003 | Apr 1, 2004 | Jan 11, 2007 | 41 | United States |
| Name | Type | Description |
|---|---|---|
| DVS-233 SR | DRUG | - |
Inclusion Criteria: 1. Generally healthy, postmenopausal women; at least 12 months of spontaneous amenorrhea or at least 6 months of spontaneous amenorrhea with serum FSH levels \> 40 mIU/mL or at least 6 weeks postsurgical bilateral oophorectomy (with or without hysterectomy). 2. Minimum of 7 mode...